Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Solid Tumor: early-phase trial registry
37 of 53 indexed Metastatic Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 37 currently recruiting · #265 of 28,707 conditions by registered trial count
Metastatic Solid Tumor: 53 US clinical trials tracked, 37 recruiting.
Metastatic Solid Tumor is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 4 of these trials.
Enrollment posture brief
Registry condition metastatic-solid-tumor
OPEN 37 | RECR 70% | LATE 0 | EARLY 50 | RANK #265 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Metastatic Solid Tumor lists 37 open slots (70% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Solid Tumor is recruiting above its size-band peers.
37 of 53 indexed trials (69.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Solid Tumor trials is spread across many organizations.
Eli Lilly and Company accounts for 4 of 53 trials (7.5%). 43 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Solid Tumor enrolment sits around 130 participants.
Median target enrolment is 130 among the 53 trials that report a genuine target (sentinel values excluded). 22 of those (41.5%) plan for fewer than 100 participants.
-
Metastatic Solid Tumor research is mostly interventional.
51 interventional and 2 observational studies make up this index (96.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 2 of 2
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04447651
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo
NCT04474470
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
Masonic Cancer Center, University of Minnesota
NCT05809557
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Solid Tumor page
53 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Metastatic Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Metastatic Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Solid Tumor condition card totals 53 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.